1
|
Almeida MC, Eger SJ, He C, Audouard M, Nikitina A, Glasauer SMK, Han D, Mejía-Cupajita B, Acosta-Uribe J, Villalba-Moreno ND, Littau JL, Elcheikhali M, Rivera EK, Carrettiero DC, Villegas-Lanau CA, Sepulveda-Falla D, Lopera F, Kosik KS. Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection. Neuron 2024:S0896-6273(24)00093-X. [PMID: 38417436 DOI: 10.1016/j.neuron.2024.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 01/07/2024] [Accepted: 02/09/2024] [Indexed: 03/01/2024]
Abstract
Highly penetrant autosomal dominant Alzheimer's disease (ADAD) comprises a distinct disease entity as compared to the far more prevalent form of AD in which common variants collectively contribute to risk. The downstream pathways that distinguish these AD forms in specific cell types have not been deeply explored. We compared single-nucleus transcriptomes among a set of 27 cases divided among PSEN1-E280A ADAD carriers, sporadic AD, and controls. Autophagy genes and chaperones clearly defined the PSEN1-E280A cases compared to sporadic AD. Spatial transcriptomics validated the activation of chaperone-mediated autophagy genes in PSEN1-E280A. The PSEN1-E280A case in which much of the brain was spared neurofibrillary pathology and harbored a homozygous APOE3-Christchurch variant revealed possible explanations for protection from AD pathology including overexpression of LRP1 in astrocytes, increased expression of FKBP1B, and decreased PSEN1 expression in neurons. The unique cellular responses in ADAD and sporadic AD require consideration when designing clinical trials.
Collapse
Affiliation(s)
- Maria Camila Almeida
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA; Center for Natural and Humans Sciences, Federal University of ABC, Sao Bernardo do Campo, SP 09608020, Brazil
| | - Sarah J Eger
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Caroline He
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Morgane Audouard
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Arina Nikitina
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Stella M K Glasauer
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Dasol Han
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Barbara Mejía-Cupajita
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA; Grupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellín 050010, Colombia
| | - Juliana Acosta-Uribe
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA; Grupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellín 050010, Colombia
| | - Nelson David Villalba-Moreno
- Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Jessica Lisa Littau
- Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Megan Elcheikhali
- Department of Statistics and Applied Probability, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Erica Keane Rivera
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
| | - Daniel Carneiro Carrettiero
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA; Center for Natural and Humans Sciences, Federal University of ABC, Sao Bernardo do Campo, SP 09608020, Brazil
| | | | - Diego Sepulveda-Falla
- Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Francisco Lopera
- Grupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellín 050010, Colombia.
| | - Kenneth S Kosik
- Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.
| |
Collapse
|
2
|
Le Guen Y, Raulin AC, Logue MW, Sherva R, Belloy ME, Eger SJ, Chen A, Kennedy G, Kuchenbecker L, O’Leary JP, Zhang R, Merritt VC, Panizzon MS, Hauger RL, Gaziano JM, Bu G, Thornton TA, Farrer LA, Napolioni V, He Z, Greicius MD. Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease. JAMA 2023; 329:551-560. [PMID: 36809323 PMCID: PMC9945061 DOI: 10.1001/jama.2023.0268] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Accepted: 12/31/2022] [Indexed: 02/23/2023]
Abstract
Importance Numerous studies have established the association of the common APOE ε2 and APOE ε4 alleles with Alzheimer disease (AD) risk across ancestries. Studies of the interaction of these alleles with other amino acid changes on APOE in non-European ancestries are lacking and may improve ancestry-specific risk prediction. Objective To determine whether APOE amino acid changes specific to individuals of African ancestry modulate AD risk. Design, Setting, and Participants Case-control study including 31 929 participants and using a sequenced discovery sample (Alzheimer Disease Sequencing Project; stage 1) followed by 2 microarray imputed data sets derived from the Alzheimer Disease Genetic Consortium (stage 2, internal replication) and the Million Veteran Program (stage 3, external validation). This study combined case-control, family-based, population-based, and longitudinal AD cohorts, which recruited participants (1991-2022) in primarily US-based studies with 1 US/Nigerian study. Across all stages, individuals included in this study were of African ancestry. Exposures Two APOE missense variants (R145C and R150H) were assessed, stratified by APOE genotype. Main Outcomes and Measures The primary outcome was AD case-control status, and secondary outcomes included age at AD onset. Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In stage 2, across multiple cohorts, 1201 cases (median age, 75 [IQR, 69-81] years; 30.8% male) and 2744 controls (median age, 80 [IQR, 75-84] years; 31.4% male) were included. In stage 3, 733 cases (median age, 79.4 [IQR, 73.8-86.5] years; 97.0% male) and 19 406 controls (median age, 71.9 [IQR, 68.4-75.8] years; 94.5% male) were included. In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10-6) and was associated with a reported younger age at AD onset (β, -5.87 years; 95% CI, -8.35 to -3.4 years; P = 3.4 × 10-6). Association with increased AD risk was replicated in stage 2 (R145C was present in 23 individuals with AD [4.7%] and 21 controls [2.7%]; OR, 2.20; 95% CI, 1.04-4.65; P = .04) and was concordant in stage 3 (R145C was present in 11 individuals with AD [3.8%] and 149 controls [2.7%]; OR, 1.90; 95% CI, 0.99-3.64; P = .051). Association with earlier AD onset was replicated in stage 2 (β, -5.23 years; 95% CI, -9.58 to -0.87 years; P = .02) and stage 3 (β, -10.15 years; 95% CI, -15.66 to -4.64 years; P = 4.0 × 10-4). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H. Conclusions and Relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.
Collapse
Affiliation(s)
- Yann Le Guen
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
- Institut du Cerveau–Paris Brain Institute–ICM, Paris, France
| | | | - Mark W. Logue
- National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, Massachusetts
- Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts
- Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
| | - Richard Sherva
- Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts
| | - Michael E. Belloy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
| | - Sarah J. Eger
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
| | - Annabel Chen
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
| | - Gabriel Kennedy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
| | | | | | - Rui Zhang
- National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, Massachusetts
| | - Victoria C. Merritt
- Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, California
- Department of Psychiatry, University of California, San Diego, La Jolla
- VA San Diego Healthcare System, San Diego, California
| | - Matthew S. Panizzon
- Department of Psychiatry, University of California, San Diego, La Jolla
- Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla
- Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Richard L. Hauger
- Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, California
- Department of Psychiatry, University of California, San Diego, La Jolla
- Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla
| | - J. Michael Gaziano
- Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston
| | - Guojun Bu
- Department of Neuroscience, Mayo Clinic, Jacksonville, Florida
| | | | - Lindsay A. Farrer
- Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts
| | - Valerio Napolioni
- School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy
| | - Zihuai He
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
- Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, California
| | - Michael D. Greicius
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
| |
Collapse
|
3
|
Belloy ME, Guen YL, Eger SJ, Napolioni V, He Z, Mormino EC, Greicius MD. GWAS of Genetic Resilience to Age‐Related Risk for Alzheimer’s Disease in Admixed African Ancestry Individuals. Alzheimers Dement 2022. [DOI: 10.1002/alz.065315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Yann Le Guen
- Stanford University Stanford CA USA
- Institut du Cerveau ‐ Paris Brain Institute ‐ ICM Paris CA France
| | | | | | | | | | | |
Collapse
|
4
|
Guen YL, Belloy ME, Grenier‐Boley B, de Rojas I, Castillo A, Jansen IE, Nicolas A, Bellenguez C, Dalmasso C, Küçükali F, Eger SJ, Álvarez‐Martínez V, Arosio B, Benussi L, Boland A, Borroni B, Bullido MJ, Caffarra P, Clarimón J, Daian D, Daniele A, Debette S, Deleuze J, Dichgans M, Dufouil C, Duzel E, Galimberti D, García‐Alberca JM, García‐González P, Giedraitis V, Grimmer T, Graff C, Grunblatt E, Hanon O, Hausner L, Heilmann‐Heimbach S, Holstege H, Hort J, Jurgen D, Kuulasmaa T, van der Lugt A, Masullo C, Mecocci P, Mehrabian S, de Mendonça A, Boada M, Mir P, Moebus S, Moreno F, Nacmias B, Nicolas G, Papenberg G, Parnetti L, Pasquier F, Pastor P, Peters O, Pijnenburg YA, Piñol‐Ripoll G, Popp J, Molina L, Puerta R, Pérez‐Tur J, Rainero I, Ramakers IH, Rasmussen KL, Real LM, Riedel‐Heller SG, Rodríguez ER, Royo JL, Rujescu D, Scarmeas N, Scheltens P, Scherbaum N, Schneider A, Seripa D, Soininen H, Solfrizzi V, Spalletta G, Squassina A, van Swieten JC, Sanchez‐Valle R, Tegos T, Thomassen JQ, Tremolizzo L, Verhey FR, Vyhnalek M, Wiltfang J, He Z, Napolioni V, Amouyel P, Jessen F, Kehoe PG, van Duijn CM, Tsolaki M, Sanchez‐Juan P, Sleegers K, Ingelsson M, Rossi G, Hiltunen M, Sims R, van der Flier WM, Ramirez A, Andreassen O, Frikke‐Schmidt R, Williams J, Ruiz A, Lambert J, Greicius MD. Rare missense variant (R251G) on
APOE
counterbalances the Alzheimer’s disease risk associated with
APOE‐ε4. Alzheimers Dement 2022. [DOI: 10.1002/alz.060114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Yann Le Guen
- Institut du Cerveau ‐ Paris Brain Institute ‐ ICM Paris CA France
- Stanford University Stanford CA USA
| | | | - Benjamin Grenier‐Boley
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167‐RID‐AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F‐59000 Lille France
| | - Itziar de Rojas
- Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya Barcelona Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III Madrid Spain
| | - Atahualpa Castillo
- UKDRI Cardiff, School of Medicine, Cardiff University, Wales, UK Cardiff United Kingdom
| | - Iris E Jansen
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Aude Nicolas
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167‐RID‐AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F‐59000 Lille France
| | - Céline Bellenguez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167‐RID‐AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F‐59000 Lille France
| | - Carolina Dalmasso
- Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne Cologne Germany
| | | | | | - Victoria Álvarez‐Martínez
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) Oviedo Spain
- Hospital Universitario Central de Asturias Oviedo Spain
| | - Beatrice Arosio
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy Milan 20122 Italy
| | - Luisa Benussi
- IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli Brescia Italy
| | - Anne Boland
- Centre National de Génotypage, Institut de Génomique / CEA Evry France
| | - Barbara Borroni
- Centre for Neurodegenerative disorders, Neurology unit, Department of Clinical and Experimental Sciences, University of Brescia Brescia Italy
| | - María J. Bullido
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III Madrid Spain
| | - Paolo Caffarra
- Centre for Cognitive Disordes and Dementia (CDCD), AUSL Parma Italy
| | - Jordi Clarimón
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Delphine Daian
- Université Paris‐Saclay, CEA National de Recherche en Génomique Humaine Centre Evry France
| | | | | | | | - Martin Dichgans
- Institute for Stroke and Dementia Research, Klinikum der Universität München Munich Germany
| | | | - Emrah Duzel
- Institute of Cognitive Neurology and Dementia Research (IKND), Otto‐von‐Guericke University Magdeburg Germany
| | - Daniela Galimberti
- Fondazione IRCCS Ca’ Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit Milan Italy
| | | | - Pablo García‐González
- Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya Barcelona Spain
| | - Vilmantas Giedraitis
- Dept.of Public Health and Caring Sciences / Geriatrics, Uppsala University Uppsala Sweden
| | - Timo Grimmer
- Klinikum rechts der Isar, Technical University of Munich, School of Medicine Munich Germany
| | - Caroline Graff
- Unit for Hereditary Dementia, Theme Inflammation and Aging, Karolinska University Hospital‐Solna Stockholm Sweden
| | - Edna Grunblatt
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich Zurich Switzerland
| | | | - Lucrezia Hausner
- Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg Mannheim Germany
| | | | - Henne Holstege
- Section Genomics of Neurodegenerative Diseases and Aging, Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Jakub Hort
- Charles University, 2nd Faculty of Medicine, Motol University Hospital, Prague, Czech Republic Prague Czech Republic
| | - Deckert Jurgen
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg Würzburg Germany
| | - Teemu Kuulasmaa
- Institute of Biomedicine, University of Eastern Finland, Joensuu, Kuopio, Eastern Finland Kuopio Finland
| | | | - Carlo Masullo
- Institute of Neurology, Catholic University of the Sacred Heart Rome Italy
| | - Patrizia Mecocci
- Institute of Gerontology and Geriatrics, Department of Medicine, University of Perugia Perugia Italy
| | - Shima Mehrabian
- Clinic of Neurology, UH “Alexandrovska”, Medical University ‐ Sofia Sofia Bulgaria
| | | | - Mercè Boada
- Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya Barcelona Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III Madrid Spain
| | - Pablo Mir
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III Madrid Spain
| | - Susanne Moebus
- Institute of Medical Informatics, Biometry und Epidemiology, University Hospital of Essen Essen Germany
| | - Fermin Moreno
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III Madrid Spain
| | - Benedetta Nacmias
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence Florence Italy
| | - Gaël Nicolas
- Inserm U1245 / Rouen University Hospital Rouen France
| | - Goran Papenberg
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University Stockholm Sweden
| | | | | | - Pau Pastor
- Fundació Docència i Recerca MútuaTerrassa and Movement Disorders Unit, Department of Neurology, University Hospital Mútua Terrassa Terrassa Spain
| | - Oliver Peters
- Department of Psychiatry, Charité‐Universitätsmedizin Berlin Berlin Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin Germany
| | - Yolande A.L. Pijnenburg
- Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | | | - Julius Popp
- University Hospital of Psychiatry Zürich Zürich Switzerland
| | - Laura Molina
- Alzheimer’s disease and other cognitive disorders Unit. Neurology Service‐ICN, Hospital Clínic de Barcelona Barcelona Spain
- Neurological Tissue Bank ‐ IDIBAPS/Hospital Clínic Barcelona Barcelona Spain
| | - Raquel Puerta
- Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya Barcelona Spain
| | - Jordi Pérez‐Tur
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III Madrid Spain
| | - Innocenzo Rainero
- Department of Neuroscience “Rita Levi Montalcini”, University of Torino Torino Italy
| | | | - Katrine Laura Rasmussen
- Department of Clinical Biochemistry, Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark
| | - Luis Miguel Real
- Departamento de Especialidades Quirúrgicas, Bioquímicas e Inmunología, School of Medicine, University of Málaga Málaga Spain
| | - Steffi G. Riedel‐Heller
- Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig Leipzig Germany
| | - Eloy Rodríguez Rodríguez
- Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL) Santander Spain
| | - José Luís Royo
- Depatamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. Facultad de Medicina. Universidad de Málaga Malaga Spain
| | - Dan Rujescu
- Department of Psychiatry, University Medicine, Halle/Saale Germany
| | - Nikolaos Scarmeas
- 1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School Athens Greece
- Columbia University Medical Center New York NY USA
| | | | - Norbert Scherbaum
- LVR‐Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg‐Essen Essen Germany
| | - Anja Schneider
- Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn Medical Center Bonn Germany
| | - Davide Seripa
- Laboratory for Advanced Hematological Diagnostics, Department of Hematology and Stem Cell Transplant Lecce Italy
| | | | - Vincenzo Solfrizzi
- Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unit, University of Bari “A. Moro Bari Italy
| | | | - Alessio Squassina
- Department of Biomedical Sciences, University of Cagliari Cagliari Italy
| | | | - Raquel Sanchez‐Valle
- Alzheimer’s disease and other cognitive disorders unit. Service of Neurology. Hospital Clínic of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona Barcelona Spain
| | - Thomas Tegos
- 1st Department of Neurology, Medical school, Aristotle University of Thessaloniki Thessaloniki Greece
| | - Jesper Qvist Thomassen
- Department of Clinical Biochemistry, Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark
| | - Lucio Tremolizzo
- Neurology, “San Gerardo” hospital, Monza and University of Milano‐Bicocca Milan Italy
| | | | - Martin Vyhnalek
- International Clinical Research Centre (ICRC), St. Anne’s University Hospital Brno Czech Republic
| | - Jens Wiltfang
- University Medical Center, University of Goettingen Goettingen Germany
| | | | | | - Philippe Amouyel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, UMR1167 Lille France
| | - Frank Jessen
- Department of Psychiatry, University of Cologne, Medical Faculty Cologne Germany
| | - Patrick G Kehoe
- Translational Health Sciences, Bristol Medical School, University of Bristol Bristol United Kingdom
| | - Cornelia M van Duijn
- Nuffield Department of Population Health, University of Oxford Oxford United Kingdom
- Department of Epidemiology, Erasmus Medical Center Rotterdam Netherlands
| | - Magda Tsolaki
- 1st Department of Neurology, Medical school, Aristotle University of Thessaloniki Thessaloniki Greece
| | - Pascual Sanchez‐Juan
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III Madrid Spain
| | | | - Martin Ingelsson
- Department of Public Health and Caring Sciences / Geriatrics, Uppsala University Uppsala Sweden
| | - Giacomina Rossi
- Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
| | - Mikko Hiltunen
- Institute of Biomedicine, University of Eastern Finland, Joensuu, Kuopio, Eastern Finland Kuopio Finland
| | - Rebecca Sims
- Division of Psychological Medicine and Clinical Neurosciences, Cardiff University Cardiff United Kingdom
| | - Wiesje M. van der Flier
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Alfredo Ramirez
- Department of Psychiatry and Psychotherapy, University of Bonn Bonn Germany
- Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne Cologne Germany
| | - Ole Andreassen
- NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
| | - Ruth Frikke‐Schmidt
- Department of Clinical Biochemistry, Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark
| | - Julie Williams
- UK Dementia Research Institute, Cardiff University Cardiff United Kingdom
| | - Agustin Ruiz
- Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya Barcelona Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III Madrid Spain
| | - Jean‐Charles Lambert
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167‐RID‐AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F‐59000 Lille France
| | | |
Collapse
|
5
|
Belloy ME, Le Guen Y, Eger SJ, Napolioni V, Greicius MD, He Z. A Fast and Robust Strategy to Remove Variant-Level Artifacts in Alzheimer Disease Sequencing Project Data. Neurol Genet 2022; 8:e200012. [PMID: 35966919 PMCID: PMC9372872 DOI: 10.1212/nxg.0000000000200012] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 05/31/2022] [Indexed: 02/02/2023]
Abstract
Background and Objectives Exome sequencing (ES) and genome sequencing (GS) are expected to be critical to further elucidate the missing genetic heritability of Alzheimer disease (AD) risk by identifying rare coding and/or noncoding variants that contribute to AD pathogenesis. In the United States, the Alzheimer Disease Sequencing Project (ADSP) has taken a leading role in sequencing AD-related samples at scale, with the resultant data being made publicly available to researchers to generate new insights into the genetic etiology of AD. To achieve sufficient power, the ADSP has adapted a study design where subsets of larger AD cohorts are collected and sequenced across multiple centers, using a variety of sequencing platforms. This approach may lead to variable variant quality across sequencing centers and/or platforms. In this study, we sought to implement and evaluate filters that can be applied fast to robustly remove variant-level artifacts in the ADSP data. Methods We implemented a robust quality control procedure to handle ADSP data. We evaluated this procedure while performing exome-wide and genome-wide association analyses on AD risk using the latest ADSP whole ES (WES) and whole GS (WGS) data releases (NG00067.v5). Results We observed that many variants displayed large variation in allele frequencies across sequencing centers/platforms and contributed to spurious association signals with AD risk. We also observed that sequencing platform/center adjustment in association models could not fully account for these spurious signals. To address this issue, we designed and implemented variant filters that could capture and remove these center-specific/platform-specific artifactual variants. Discussion We derived a fast and robust approach to filter variants that represent sequencing center-related or platform-related artifacts underlying spurious associations with AD risk in ADSP WES and WGS data. This approach will be important to support future robust genetic association studies on ADSP data, as well as other studies with similar designs.
Collapse
|
6
|
Le Guen Y, Belloy ME, Grenier-Boley B, de Rojas I, Castillo-Morales A, Jansen I, Nicolas A, Bellenguez C, Dalmasso C, Küçükali F, Eger SJ, Rasmussen KL, Thomassen JQ, Deleuze JF, He Z, Napolioni V, Amouyel P, Jessen F, Kehoe PG, van Duijn C, Tsolaki M, Sánchez-Juan P, Sleegers K, Ingelsson M, Rossi G, Hiltunen M, Sims R, van der Flier WM, Ramirez A, Andreassen OA, Frikke-Schmidt R, Williams J, Ruiz A, Lambert JC, Greicius MD, Arosio B, Benussi L, Boland A, Borroni B, Caffarra P, Daian D, Daniele A, Debette S, Dufouil C, Düzel E, Galimberti D, Giedraitis V, Grimmer T, Graff C, Grünblatt E, Hanon O, Hausner L, Heilmann-Heimbach S, Holstege H, Hort J, Jürgen D, Kuulasmaa T, van der Lugt A, Masullo C, Mecocci P, Mehrabian S, de Mendonça A, Moebus S, Nacmias B, Nicolas G, Olaso R, Papenberg G, Parnetti L, Pasquier F, Peters O, Pijnenburg YAL, Popp J, Rainero I, Ramakers I, Riedel-Heller S, Scarmeas N, Scheltens P, Scherbaum N, Schneider A, Seripa D, Soininen H, Solfrizzi V, Spalletta G, Squassina A, van Swieten J, Tegos TJ, Tremolizzo L, Verhey F, Vyhnalek M, Wiltfang J, Boada M, García-González P, Puerta R, Real LM, Álvarez V, Bullido MJ, Clarimon J, García-Alberca JM, Mir P, Moreno F, Pastor P, Piñol-Ripoll G, Molina-Porcel L, Pérez-Tur J, Rodríguez-Rodríguez E, Royo JL, Sánchez-Valle R, Dichgans M, Rujescu D. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurol 2022; 79:652-663. [PMID: 35639372 PMCID: PMC9157381 DOI: 10.1001/jamaneurol.2022.1166] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Importance The APOE ε2 and APOE ε4 alleles are the strongest protective and risk-increasing, respectively, genetic variants for late-onset Alzheimer disease (AD). However, the mechanisms linking APOE to AD-particularly the apoE protein's role in AD pathogenesis and how this is affected by APOE variants-remain poorly understood. Identifying missense variants in addition to APOE ε2 and APOE ε4 could provide critical new insights, but given the low frequency of additional missense variants, AD genetic cohorts have previously been too small to interrogate this question robustly. Objective To determine whether rare missense variants on APOE are associated with AD risk. Design, Setting, and Participants Association with case-control status was tested in a sequenced discovery sample (stage 1) and followed up in several microarray imputed cohorts as well as the UK Biobank whole-exome sequencing resource using a proxy-AD phenotype (stages 2 and 3). This study combined case-control, family-based, population-based, and longitudinal AD-related cohorts that recruited referred and volunteer participants. Stage 1 included 37 409 nonunique participants of European or admixed European ancestry, with 11 868 individuals with AD and 11 934 controls passing analysis inclusion criteria. In stages 2 and 3, 475 473 participants were considered across 8 cohorts, of which 84 513 individuals with AD and proxy-AD and 328 372 controls passed inclusion criteria. Selection criteria were cohort specific, and this study was performed a posteriori on individuals who were genotyped. Among the available genotypes, 76 195 were excluded. All data were retrieved between September 2015 and November 2021 and analyzed between April and November 2021. Main Outcomes and Measures In primary analyses, the AD risk associated with each missense variant was estimated, as appropriate, with either linear mixed-model regression or logistic regression. In secondary analyses, associations were estimated with age at onset using linear mixed-model regression and risk of conversion to AD using competing-risk regression. Results A total of 544 384 participants were analyzed in the primary case-control analysis; 312 476 (57.4%) were female, and the mean (SD; range) age was 64.9 (15.2; 40-110) years. Two missense variants were associated with a 2-fold to 3-fold decreased AD risk: APOE ε4 (R251G) (odds ratio, 0.44; 95% CI, 0.33-0.59; P = 4.7 × 10-8) and APOE ε3 (V236E) (odds ratio, 0.37; 95% CI, 0.25-0.56; P = 1.9 × 10-6). Additionally, the cumulative incidence of AD in carriers of these variants was found to grow more slowly with age compared with noncarriers. Conclusions and Relevance In this genetic association study, a novel variant associated with AD was identified: R251G always coinherited with ε4 on the APOE gene, which mitigates the ε4-associated AD risk. The protective effect of the V236E variant, which is always coinherited with ε3 on the APOE gene, was also confirmed. The location of these variants confirms that the carboxyl-terminal portion of apoE plays an important role in AD pathogenesis. The large risk reductions reported here suggest that protein chemistry and functional assays of these variants should be pursued, as they have the potential to guide drug development targeting APOE.
Collapse
Affiliation(s)
- Yann Le Guen
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.,Institut du Cerveau, Paris Brain Institute, Paris, France
| | - Michael E Belloy
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California
| | - Benjamin Grenier-Boley
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Itziar de Rojas
- Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.,Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Iris Jansen
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, the Netherlands
| | - Aude Nicolas
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Céline Bellenguez
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Carolina Dalmasso
- Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.,Estudios en Neurociencias y Sistemas Complejos (ENyS) CONICET-HEC-UNAJ, Universidad Nacional Arturo Jauretche, Florencio Varela, Argentina
| | - Fahri Küçükali
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.,Laboratory of Neurogenetics, Born-Bunge Institute, Antwerp, Belgium.,Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Sarah J Eger
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California
| | - Katrine Laura Rasmussen
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Jesper Qvist Thomassen
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Jean-François Deleuze
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France
| | - Zihuai He
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.,Quantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, California
| | - Valerio Napolioni
- School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy
| | - Philippe Amouyel
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Frank Jessen
- Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
| | - Patrick G Kehoe
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - Cornelia van Duijn
- Department of Epidemiology, ErasmusMC, Rotterdam, the Netherlands.,Nuffield Department of Population Health Oxford University, Oxford, United Kingdom
| | - Magda Tsolaki
- 1st Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Pascual Sánchez-Juan
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Alzheimer's Centre Reina Sofia-CIEN Foundation, Madrid, Spain
| | - Kristel Sleegers
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.,Laboratory of Neurogenetics, Born-Bunge Institute, Antwerp, Belgium.,Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Martin Ingelsson
- Department of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden.,Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.,Department of Medicine and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
| | - Giacomina Rossi
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Mikko Hiltunen
- Institute of Biomedicine, University of Eastern Finland, Joensuu, Kuopio, Finland
| | - Rebecca Sims
- Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Wiesje M van der Flier
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands
| | - Alfredo Ramirez
- Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.,Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.,Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, The University of Texas Health Science Center at San Antonio
| | - Ole A Andreassen
- NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Ruth Frikke-Schmidt
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Julie Williams
- UKDRI@Cardiff, School of Medicine, Cardiff University, Cardiff, United Kingdom.,Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Agustín Ruiz
- Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.,Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Jean-Charles Lambert
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Michael D Greicius
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California
| | | | - Beatrice Arosio
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Luisa Benussi
- Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Anne Boland
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | - Delphine Daian
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France
| | - Antonio Daniele
- Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.,Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| | - Stéphanie Debette
- University Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.,Department of Neurology, Bordeaux University Hospital, Bordeaux, France
| | - Carole Dufouil
- Inserm, Bordeaux Population Health Research Center, UMR 1219, University of Bordeaux, ISPED, CIC 1401-EC, Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Pole santé publique, Bordeaux, France
| | - Emrah Düzel
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.,Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany
| | - Daniela Galimberti
- Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy.,Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Vilmantas Giedraitis
- Department of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden
| | - Timo Grimmer
- Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany
| | - Caroline Graff
- Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden
| | - Edna Grünblatt
- Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.,Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.,Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Olivier Hanon
- Université de Paris, EA 4468, APHP, Hôpital Broca, Paris, France
| | - Lucrezia Hausner
- Department of Geriatric Psychiatry, Central Institute of Mental Health Mannheim, Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
| | - Stefanie Heilmann-Heimbach
- Institute of Human Genetics, University of Bonn, School of Medicine, University Hospital Bonn, Bonn, Germany
| | - Henne Holstege
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Clinical Genetics, VU University Medical Centre, Amsterdam, the Netherlands
| | - Jakub Hort
- Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.,International Clinical Research Center, St Anne's University Hospital Brno, Brno, Czech Republic
| | - Deckert Jürgen
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany
| | - Teemu Kuulasmaa
- Institute of Biomedicine, University of Eastern Finland, Joensuu, Kuopio, Finland
| | - Aad van der Lugt
- Department of Radiology and Nuclear Medicine, ErasmusMC, Rotterdam, the Netherlands
| | - Carlo Masullo
- Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy
| | - Patrizia Mecocci
- Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - Shima Mehrabian
- Clinic of Neurology, UH Alexandrovska, Medical University Sofia, Sofia, Bulgaria
| | | | - Susanne Moebus
- Institute for Urban Public Health, University Hospital of University Duisburg-Essen, Essen, Germany
| | - Benedetta Nacmias
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.,IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
| | - Gael Nicolas
- Normandie Université, UNIROUEN, Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Rouen, France
| | - Robert Olaso
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France
| | - Goran Papenberg
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden
| | - Lucilla Parnetti
- Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, Perugia, Italy
| | - Florence Pasquier
- Université de Lille, Inserm 1172, CHU Clinical and Research Memory Research Centre (CMRR) of Distalz, Lille, France
| | - Oliver Peters
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Berlin, Germany
| | - Yolande A L Pijnenburg
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands
| | - Julius Popp
- Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.,Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zurich, Switzerland.,Institute for Regenerative Medicine, University of Zürich, Zurich, Switzerland
| | - Innocenzo Rainero
- Department of Neuroscience "Rita Levi Montalcini," University of Torino, Torino, Italy
| | - Inez Ramakers
- Maastricht University, Department of Psychiatry and Neuropsychologie, Alzheimer Center Limburg, Maastricht, the Netherlands
| | - Steffi Riedel-Heller
- Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
| | - Nikolaos Scarmeas
- 1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.,Taub Institute for Research in Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, New York
| | - Philip Scheltens
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands
| | - Norbert Scherbaum
- LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany
| | - Anja Schneider
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
| | - Davide Seripa
- Laboratory for Advanced Hematological Diagnostics, Department of Hematology and Stem Cell Transplant, "Vito Fazzi" Hospital, Lecce, Italy
| | - Hilkka Soininen
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland
| | - Vincenzo Solfrizzi
- Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unit, University of Bari Aldo Moro, Bari, Italy
| | - Gianfranco Spalletta
- Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.,Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas
| | - Alessio Squassina
- Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
| | | | - Thomas J Tegos
- 1st Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Lucio Tremolizzo
- Neurology, "San Gerardo" Hospital, Monza and University of Milano-Bicocca, Milan, Italy
| | - Frans Verhey
- Maastricht University, Department of Psychiatry and Neuropsychologie, Alzheimer Center Limburg, Maastricht, the Netherlands
| | - Martin Vyhnalek
- Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.,International Clinical Research Center, St Anne's University Hospital Brno, Brno, Czech Republic
| | - Jens Wiltfang
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.,German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.,Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
| | - Mercè Boada
- Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.,Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Pablo García-González
- Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.,Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Raquel Puerta
- Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Luis M Real
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, Spain.,Depatamento de Especialidades Quirúrgicas, Bioquímica e Inmunología, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
| | - Victoria Álvarez
- Laboratorio de Genética, Hospital Universitario Central de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - María J Bullido
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain
| | - Jordi Clarimon
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - José María García-Alberca
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Alzheimer Research Center & Memory Clinic, Andalusian Institute for Neuroscience, Málaga, Spain
| | - Pablo Mir
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
| | - Fermin Moreno
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.,Neurosciences Area, Instituto Biodonostia, San Sebastian, Spain
| | - Pau Pastor
- Fundació Docència i Recerca MútuaTerrassa, Terrassa, Spain.,Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Spain
| | - Gerard Piñol-Ripoll
- Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.,Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain
| | - Laura Molina-Porcel
- Neurological Tissue Bank (Biobanc), Hospital Clinic IDIBAPS, Barcelona, Spain.,Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain
| | - Jordi Pérez-Tur
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain.,Unidad Mixta de Neurologia Genètica, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - Eloy Rodríguez-Rodríguez
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.,Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain
| | - Jose Luís Royo
- Depatamento de Especialidades Quirúrgicas, Bioquímica e Inmunología, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
| | - Raquel Sánchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - Martin Dichgans
- Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.,German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Dan Rujescu
- Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria
| |
Collapse
|
7
|
Belloy ME, Eger SJ, Le Guen Y, Damotte V, Ahmad S, Ikram MA, Ramirez A, Tsolaki AC, Rossi G, Jansen IE, de Rojas I, Parveen K, Sleegers K, Ingelsson M, Hiltunen M, Amin N, Andreassen O, Sánchez-Juan P, Kehoe P, Amouyel P, Sims R, Frikke-Schmidt R, van der Flier WM, Lambert JC, He Z, Han SS, Napolioni V, Greicius MD. Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimers Res Ther 2022; 14:22. [PMID: 35120553 PMCID: PMC8815198 DOI: 10.1186/s13195-022-00962-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 01/12/2022] [Indexed: 04/22/2023]
Abstract
BACKGROUND Genetic variants within the APOE locus may modulate Alzheimer's disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our understanding of APOE pathophysiology and provide critical guidance for AD therapies aimed at APOE. The APOE locus however remains relatively poorly understood in AD, owing to multiple challenges that include its complex linkage structure and uncertainty in APOE*2/3/4 genotype quality. Here, we present a novel APOE*2/3/4 filtering approach and showcase its relevance on AD risk association analyses for the rs439401 variant, which is located 1801 base pairs downstream of APOE and has been associated with a potential regulatory effect on APOE. METHODS We used thirty-two AD-related cohorts, with genetic data from various high-density single-nucleotide polymorphism microarrays, whole-genome sequencing, and whole-exome sequencing. Study participants were filtered to be ages 60 and older, non-Hispanic, of European ancestry, and diagnosed as cognitively normal or AD (n = 65,701). Primary analyses investigated AD risk in APOE*4/4 carriers. Additional supporting analyses were performed in APOE*3/4 and 3/3 strata. Outcomes were compared under two different APOE*2/3/4 filtering approaches. RESULTS Using more conventional APOE*2/3/4 filtering criteria (approach 1), we showed that, when in-phase with APOE*4, rs439401 was variably associated with protective effects on AD case-control status. However, when applying a novel filter that increases the certainty of the APOE*2/3/4 genotypes by applying more stringent criteria for concordance between the provided APOE genotype and imputed APOE genotype (approach 2), we observed that all significant effects were lost. CONCLUSIONS We showed that careful consideration of APOE genotype and appropriate sample filtering were crucial to robustly interrogate the role of the APOE locus on AD risk. Our study presents a novel APOE filtering approach and provides important guidelines for research into the APOE locus, as well as for elucidating genetic interaction effects with APOE*2/3/4.
Collapse
Affiliation(s)
- Michael E Belloy
- Department of Neurology and Neurological Sciences - Greicius lab, Stanford University, 290 Jane Stanford Way, Stanford, CA, 94304, USA.
| | - Sarah J Eger
- Department of Neurology and Neurological Sciences - Greicius lab, Stanford University, 290 Jane Stanford Way, Stanford, CA, 94304, USA
| | - Yann Le Guen
- Department of Neurology and Neurological Sciences - Greicius lab, Stanford University, 290 Jane Stanford Way, Stanford, CA, 94304, USA
| | - Vincent Damotte
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Shahzad Ahmad
- Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
| | - M Arfan Ikram
- Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands
| | - Alfredo Ramirez
- Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Department of Neurodegenerative diseases and Geriatric Psychiatry, Medical Faculty, University Hospital Bonn, Bonn, Germany
- Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Cologne, Germany
| | - Anthoula C Tsolaki
- 1st Department of Neurology, AHEPA Hospital, Aristotle University of Thessaloniki, Athens, Greece
| | - Giacomina Rossi
- Unit of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Iris E Jansen
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
- Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, The Netherlands
| | - Itziar de Rojas
- Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Kayenat Parveen
- Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Department of Neurodegenerative diseases and Geriatric Psychiatry, Medical Faculty, University Hospital Bonn, Bonn, Germany
| | - Kristel Sleegers
- Complex Genetics of Alzheimer's Disease Group, Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Martin Ingelsson
- Department of Public Health and Carins Sciences/Geriatrics, Uppsala University, Uppsala, Sweden
| | - Mikko Hiltunen
- Institute of Biomedicine, University of Eastern Finland, Yliopistonranta 1E, 70211, Kuopio, Finland
| | - Najaf Amin
- Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands
- Nuffield Department of Population Health Oxford University, Oxford, UK
| | - Ole Andreassen
- NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Pascual Sánchez-Juan
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain
| | - Patrick Kehoe
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Philippe Amouyel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Rebecca Sims
- Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Wales, UK
| | - Ruth Frikke-Schmidt
- Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Wiesje M van der Flier
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
| | - Jean-Charles Lambert
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Zihuai He
- Department of Neurology and Neurological Sciences - Greicius lab, Stanford University, 290 Jane Stanford Way, Stanford, CA, 94304, USA
- Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, 94304, USA
| | - Summer S Han
- Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, 94304, USA
- Department of Neurosurgery, Stanford University, Stanford, CA, 94304, USA
| | - Valerio Napolioni
- School of Biosciences and Veterinary Medicine, University of Camerino, 62032, Camerino, Italy
| | - Michael D Greicius
- Department of Neurology and Neurological Sciences - Greicius lab, Stanford University, 290 Jane Stanford Way, Stanford, CA, 94304, USA
| |
Collapse
|
8
|
Eger SJ, Le Guen Y, Khan RR, Hall JN, Kennedy G, Zaharchuk G, Couthouis J, Brooks WS, Velakoulis D, Napolioni V, Belloy ME, Dalgard CL, Mormino EC, Gitler AD, Greicius MD. Confirming Pathogenicity of the F386L PSEN1 Variant in a South Asian Family With Early-Onset Alzheimer Disease. Neurol Genet 2021; 8:e647. [PMID: 34901437 PMCID: PMC8655848 DOI: 10.1212/nxg.0000000000000647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 10/20/2021] [Indexed: 11/15/2022]
Abstract
Objectives The F386L PSEN1 variant has been reported in 1 Japanese family with limited clinical information. We aimed to prove that F386L is pathogenic by demonstrating that it segregates with early-onset Alzheimer disease (AD). Methods Eight individuals in a South Asian family provided DNA for genetic testing and underwent a neurologic examination. Results The female proband was diagnosed with AD at age 45 years and died at age 49 years. She had a CSF biomarker profile consistent with AD, and her florbetaben PET scan was amyloid positive with high uptake in the striatum. Her MRI showed no prominent white matter disease. Her affected relatives had an age at onset range of 38–57 years and had imaging and biomarker profiles similar to hers. Discussion The results presented here, in conjunction with the prior report, confirm the pathogenicity of F386L. Furthermore, our study highlights the importance of studying families from underrepresented populations to identify or confirm the pathogenicity of rare variants that may be specific to certain genetic ancestries.
Collapse
Affiliation(s)
- Sarah J Eger
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Yann Le Guen
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Raiyan R Khan
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Jacob N Hall
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Gabriel Kennedy
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Greg Zaharchuk
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Julien Couthouis
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - William S Brooks
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Dennis Velakoulis
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Valerio Napolioni
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Michaël E Belloy
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Clifton L Dalgard
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Elizabeth C Mormino
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Aaron D Gitler
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| | - Michael D Greicius
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, (S.J.E., Y.L.G., G.K., M.E.B., E.C.M., M.D.G.); Department of Computer Science, Columbia University, New York, NY (R.R.K.) the Neurology Center of Southern California, Temecula, CA (J.N.H.); Department of Radiology, Stanford University School of Medicine, Stanford, CA (G.Z.) Department of Genetics, Stanford University School of Medicine, Stanford, CA (J.C., A.D.G.); Neuroscience Research Australia, Randwick NSW 2031, Australia (W.S.B); the University of New South Wales, Sydney NSW 2052, Australia (W.S.B.); Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville VIC 3050, Australia (D.V.); School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy (V.N); Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.); the American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD (C.L.D.)
| |
Collapse
|
9
|
Guen YL, Belloy ME, Napolioni V, Eger SJ, Kennedy G, Tao R, He Z, Greicius MD. A novel age‐informed approach for genetic association analysis in Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.050541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | | | | | | | - Gabriel Kennedy
- Department of Neurology and Neurological Sciences Stanford University Stanford CA USA
| | - Ran Tao
- Vanderbilt University Nashville TN USA
| | | | | |
Collapse
|
10
|
Le Guen Y, Napolioni V, Belloy ME, Yu E, Krohn L, Ruskey JA, Gan-Or Z, Kennedy G, Eger SJ, Greicius MD. Common X-Chromosome Variants Are Associated with Parkinson Disease Risk. Ann Neurol 2021; 90:22-34. [PMID: 33583074 PMCID: PMC8601399 DOI: 10.1002/ana.26051] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 02/12/2021] [Accepted: 02/12/2021] [Indexed: 12/14/2022]
Abstract
OBJECTIVE The objective of this study was to identify genetic variants on the X-chromosome associated with Parkinson disease (PD) risk. METHODS We performed an X-chromosome-wide association study (XWAS) of PD risk by meta-analyzing results from sex-stratified analyses. To avoid spurious associations, we designed a specific harmonization pipeline for the X-chromosome and focused on a European ancestry sample. We included 11,142 cases, 280,164 controls, and 5,379 proxy cases, based on parental history of PD. Additionally, we tested the association of significant variants with (1) PD risk in an independent replication with 1,561 cases and 2,465 controls and (2) putamen volume in 33,360 individuals from the UK Biobank. RESULTS In the discovery meta-analysis, we identified rs7066890 (odds ratio [OR] = 1.10, 95% confidence interval [CI] = 1.06-1.14, p = 2.2 × 10-9 ), intron of GPM6B, and rs28602900 (OR = 1.10, 95% CI = 1.07-1.14, p = 1.6 × 10-8 ) in a high gene density region including RPL10, ATP6A1, FAM50A, and PLXNA3. The rs28602900 association with PD was replicated (OR = 1.16, 95% CI = 1.03-1.30, p = 0.016) and shown to colocalize with a significant expression quantitative locus (eQTL) regulating RPL10 expression in the putamen and other brain tissues in the Genotype-Tissue Expression Project. Additionally, the rs28602900 locus was found to be associated with reduced brain putamen volume. No results reached genome-wide significance in the sex-stratified analyses. INTERPRETATION We report the first XWAS of PD and identify 2 genome-wide significant loci. The rs28602900 association was replicated in an independent PD dataset and showed concordant effects in its association with putamen volume. Critically, rs26802900 is a significant eQTL of RPL10. These results support a role for ribosomal proteins in PD pathogenesis and show that the X-chromosome contributes to PD genetic risk. ANN NEUROL 2021;90:22-34.
Collapse
Affiliation(s)
- Yann Le Guen
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Valerio Napolioni
- School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy
| | - Michael E Belloy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Eric Yu
- Department of Human Genetics, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
| | - Lynne Krohn
- Department of Human Genetics, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
| | - Jennifer A Ruskey
- Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Ziv Gan-Or
- Department of Human Genetics, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Gabriel Kennedy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Sarah J Eger
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Michael D Greicius
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| |
Collapse
|
11
|
Le Guen Y, Belloy ME, Napolioni V, Eger SJ, Kennedy G, Tao R, He Z, Greicius MD. A novel age-informed approach for genetic association analysis in Alzheimer's disease. Alzheimers Res Ther 2021; 13:72. [PMID: 33794991 PMCID: PMC8017764 DOI: 10.1186/s13195-021-00808-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 03/11/2021] [Indexed: 01/17/2023]
Abstract
BACKGROUND Many Alzheimer's disease (AD) genetic association studies disregard age or incorrectly account for it, hampering variant discovery. METHODS Using simulated data, we compared the statistical power of several models: logistic regression on AD diagnosis adjusted and not adjusted for age; linear regression on a score integrating case-control status and age; and multivariate Cox regression on age-at-onset. We applied these models to real exome-wide data of 11,127 sequenced individuals (54% cases) and replicated suggestive associations in 21,631 genotype-imputed individuals (51% cases). RESULTS Modeling variable AD risk across age results in 5-10% statistical power gain compared to logistic regression without age adjustment, while incorrect age adjustment leads to critical power loss. Applying our novel AD-age score and/or Cox regression, we discovered and replicated novel variants associated with AD on KIF21B, USH2A, RAB10, RIN3, and TAOK2 genes. CONCLUSION Our AD-age score provides a simple means for statistical power gain and is recommended for future AD studies.
Collapse
Affiliation(s)
- Yann Le Guen
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94304, USA.
| | - Michael E Belloy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94304, USA
| | - Valerio Napolioni
- School of Biosciences and Veterinary Medicine, University of Camerino, 62032, Camerino, Italy
| | - Sarah J Eger
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94304, USA
| | - Gabriel Kennedy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94304, USA
| | - Ran Tao
- Department of Biostatistics and Vanderbilt Genetic Institute, Vanderbilt University, Nashville, TN, 37203, USA
| | - Zihuai He
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94304, USA
- Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, 94304, USA
| | - Michael D Greicius
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94304, USA
| |
Collapse
|
12
|
Belloy ME, Eger SJ, Le Guen Y, Napolioni V, Deters KD, Yang HS, Scelsi MA, Porter T, James SN, Wong A, Schott JM, Sperling RA, Laws SM, Mormino EC, He Z, Han SS, Altmann A, Greicius MD. KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers. Neurobiol Aging 2021; 101:123-129. [PMID: 33610961 DOI: 10.1016/j.neurobiolaging.2021.01.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 11/30/2020] [Accepted: 01/09/2021] [Indexed: 11/15/2022]
Abstract
KLOTHO∗VS heterozygosity (KL∗VSHET+) was recently shown to be associated with reduced risk of Alzheimer's disease (AD) in APOE∗4 carriers. Additional studies suggest that KL∗VSHET+ protects against amyloid burden in cognitively normal older subjects, but sample sizes were too small to draw definitive conclusions. We performed a well-powered meta-analysis across 5 independent studies, comprising 3581 pre-clinical participants ages 60-80, to investigate whether KL∗VSHET+ reduces the risk of having an amyloid-positive positron emission tomography scan. Analyses were stratified by APOE∗4 status. KL∗VSHET+ reduced the risk of amyloid positivity in APOE∗4 carriers (odds ratio = 0.67 [0.52-0.88]; p = 3.5 × 10-3), but not in APOE∗4 non-carriers (odds ratio = 0.94 [0.73-1.21]; p = 0.63). The combination of APOE∗4 and KL∗VS genotypes should help enrich AD clinical trials for pre-symptomatic subjects at increased risk of developing amyloid aggregation and AD. KL-related pathways may help elucidate protective mechanisms against amyloid accumulation and merit exploration for novel AD drug targets. Future investigation of the biological mechanisms by which KL interacts with APOE∗4 and AD are warranted.
Collapse
Affiliation(s)
- Michael E Belloy
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
| | - Sarah J Eger
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Yann Le Guen
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Valerio Napolioni
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Kacie D Deters
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Hyun-Sik Yang
- Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Marzia A Scelsi
- Centre for Medical Image Computing (CMIC), University College London, London, UK
| | - Tenielle Porter
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Sarah-Naomi James
- Medical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK
| | - Andrew Wong
- Medical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK
| | - Jonathan M Schott
- Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute, University College London, London, UK
| | - Reisa A Sperling
- Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Simon M Laws
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Elisabeth C Mormino
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | - Zihuai He
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA; Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, CA, USA
| | - Summer S Han
- Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, CA, USA; Department of Neurosurgery, Stanford University, Stanford, CA, USA
| | - Andre Altmann
- Centre for Medical Image Computing (CMIC), University College London, London, UK
| | - Michael D Greicius
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
| | | | | | | | | |
Collapse
|
13
|
Belloy ME, Eger SJ, Guen YL, Napolioni V, Greicius MD. Two
APOE
splice sQTLs reduce Alzheimer’s disease risk in
APOE
4/4 carriers. Alzheimers Dement 2020. [DOI: 10.1002/alz.043539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
14
|
Guen YL, Napolioni V, Belloy ME, Eger SJ, Kennedy G, Morgan K, Greicius MD. RPS16
and
NOL6
splice region variants are associated with early onset Alzheimer's disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.040056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | | | | | | | - Kevin Morgan
- University of Nottingham Nottingham United Kingdom
| | | |
Collapse
|
15
|
Eger SJ, Belloy ME, Guen YL, Napolioni V, Deters KD, Mormino EC, Greicius MD. Klotho‐VS decreases probability of amyloid pet positivity in APOE4+ controls. Alzheimers Dement 2020. [DOI: 10.1002/alz.045360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|